Compare Honeywell International Inc (HON) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Neurocrine Biosciences Inc — how do they compare? Honeywell International Inc trades at $230.33 (market cap $76.99B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Honeywell International Inc is far larger — about 4.6× Neurocrine Biosciences Inc's market cap, and Honeywell International Inc pays a 1.15% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| HON | NBIX | |
|---|---|---|
Market Cap | $76.99B | $16.76B |
Sector | Industrials | Health |
52-Week High | $248.79 | $185.50 |
52-Week Low | $188.14 | $123.10 |
Enterprise Value | $101.79B | $16.78B |
Dividend Yield | 1.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell Technologies (HON) trades at $246.19, up 2.26% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations, and the company has completed strategic divestitures to focus on automation. Key financials show a P/E of 9.47, net income margin of 21.58%, and robust cash flow from operations of $6.41B in 2025. The stock is near its consensus price target of $320.54, indicating potential upside.
Outlook is positive due to earnings momentum and portfolio simplification, but risks include integration challenges from spinoffs and macroeconomic sensitivity. Institutional sentiment is bullish with 66.7% buy ratings. Investors should monitor execution of growth strategies in building automation and aerospace segments for sustained performance.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
